Literature DB >> 7518304

Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.

P Picard1, D Regoli, R Couture.   

Abstract

1. The effects of intracerebroventricular (i.c.v.) injection of selective and potent NK1 (RP 67580), NK2 (SR 48968) and NK3 (R 486, [Trp7, beta-Ala8]NKA(4-10)) receptor antagonists were assessed on the cardiovascular and behavioural responses elicited by the i.c.v. injection of substance P (SP), neurokinin A (NKA) or [MePhe7]neurokinin B ([MePhe7]NKB) in the conscious freely moving rat. 2. SP, NKA and [MePhe7]NKB (5-650 pmol) evoked dose-dependent increases in mean arterial blood pressure (MAP) and heart rate (HR) with the rank order of potency SP > NKA > [MePhe7]NKB. The cardiovascular responses were accompanied by excessive face washing, grooming and wet dog shakes. 3. The cardiovascular effects and face washing behaviour induced by SP (25 pmol) were significantly reduced by the pre-injection (i.c.v., 5 min earlier) of RP 67580 (6.5 nmol). However, this antagonist failed to affect the central effects of 25 pmol NKA or [MePhe7]NKB. 4. The cardiovascular and behavioural responses (except for wet dog shakes) elicited by NKA (25 pmol) were significantly reduced by 6.5 nmol SR 48968. However, the latter antagonist had no effect on the SP or [MePhe7]NKB-mediated responses. 5. Both cardiovascular and behavioural effects produced by either SP or NKA (25 pmol) were completely abolished when rats were pretreated with a combination of RP 67580 (6.5 nmol) and SR 48968 (6.5 nmol), yet this combination of antagonists failed to modify the central effects of [MePhe7]NKB. 6. R 486 (6.5 nmol) inhibited the cardiovascular effects as well as wet dog shakes produced by [MePhe7]NKB, but it was inactive against the responses induced by either SP or NKA. 7. None of the tachykinin receptor antagonists or agonists caused motor impairment or respiratory distress. All antagonists blocked in a reversible manner and were devoid of intrinsic activity except R486 (6.5 nmol) which produced a transient increase of MAP and HR.8. These results suggest that the central effects of SP, NKA and [MePhe7]NKB are primarily mediated by central NK1, NK2 and NK3 receptors, respectively. However, a minor activation of NK2 receptors bySP and NK1 receptors by NKA was seen during blockade of both receptors. This study therefore supports the existence of functional NK1, NK2 and NK3 receptors in the adult rat brain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518304      PMCID: PMC1910324          DOI: 10.1111/j.1476-5381.1994.tb13058.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  The hypothalamic paraventricular nucleus is a site of action for the central effect of tachykinins on plasma vasopressin.

Authors:  M Massi; A Saija; C Polidori; M Perfumi; L Gentili; G Costa; G de Caro
Journal:  Brain Res Bull       Date:  1991-01       Impact factor: 4.077

2.  The induction of excessive grooming in the rat by intraventricular application of peptides derived from ACTH: structure-activity studies.

Authors:  W H Gispen; V M Wiegant; H M Greven; D de Wied
Journal:  Life Sci       Date:  1975-08-15       Impact factor: 5.037

3.  The mechanism of central pressor actions of tachykinin NK-3 receptor in the paraventricular nucleus of the hypothalamus in rats.

Authors:  Y Takano; Y Nakayama; T Matsumoto; R Saito; H O Kamiya
Journal:  Regul Pept       Date:  1993-07-02

4.  Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues.

Authors:  P W Mantyh; T Gates; C R Mantyh; J E Maggio
Journal:  J Neurosci       Date:  1989-01       Impact factor: 6.167

5.  The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats.

Authors:  A J Stoessl; C T Dourish; S D Iversen
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

6.  Distribution of cells containing mRNAs encoding substance P and neurokinin B in the rat central nervous system.

Authors:  M K Warden; W S Young
Journal:  J Comp Neurol       Date:  1988-06-01       Impact factor: 3.215

7.  The distribution of substance P immunoreactive fibers in the rat central nervous system.

Authors:  A C Cuello; I Kanazawa
Journal:  J Comp Neurol       Date:  1978-03-01       Impact factor: 3.215

8.  The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences.

Authors:  S Guard; S J Boyle; K W Tang; K J Watling; A T McKnight; G N Woodruff
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin.

Authors:  T Unger; W Rascher; C Schuster; R Pavlovitch; A Schömig; R Dietz; D Ganten
Journal:  Eur J Pharmacol       Date:  1981-04-24       Impact factor: 4.432

10.  Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization.

Authors:  T Unger; S Carolus; G Demmert; D Ganten; R E Lang; C Maser-Gluth; H Steinberg; R Veelken
Journal:  Circ Res       Date:  1988-10       Impact factor: 17.367

View more
  14 in total

1.  Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.

Authors:  S B Mazzone; D P Geraghty
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 3.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

4.  Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.

Authors:  P Picard; R Couture
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

5.  Modulation of cardiac activity by tachykinins in the rat substantia nigra.

Authors:  A Lessard; R Couture
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Respiratory action of capsaicin microinjected into the nucleus of the solitary tract: involvement of vanilloid and tachykinin receptors.

Authors:  S B Mazzone; D P Geraghty
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene.

Authors:  Anika Agarwal; Lisa M Halvorson; Gabor Legradi
Journal:  Brain Res Mol Brain Res       Date:  2005-07-29

8.  Cardiovascular responses to intrathecal neuropeptide gamma in conscious rats: receptor characterization and mechanism of action.

Authors:  P Poulat; J de Champlain; R Couture
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

9.  Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

Authors:  P Picard; L Chrétien; R Couture
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

10.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

Authors:  O Piot; J Betschart; I Grall; S Ravard; C Garret; J C Blanchard
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.